Capmatinib
Krazati (adagrasib) is a prescription medication classified as a KRAS G12C inhibitor used to treat adults with KRAS G12C-mutated non-small cell lung cancer (NSCLC) that has spread to other parts of the body. It is used when the cancer has progressed after receiving at least one prior systemic therapy. This targeted therapy is specifically designed for patients whose tumors have the KRAS G12C genetic mutation.
Krazati is a targeted therapy for KRAS G12C-mutated advanced non-small cell lung cancer in adults.
Key facts at a glance
- RxNorm
- 2625918
- Generic
- Krazati
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Krazati is indicated for the treatment of adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy. Testing for the KRAS G12C mutation is required before starting treatment to confirm eligibility.
Krazati is a KRAS G12C inhibitor that works by irreversibly binding to the KRAS G12C protein, which is mutated in certain cancers. By targeting this specific mutation, the medication helps slow or stop the growth of KRAS G12C-mutated cancer cells.
Common side effects may include gastrointestinal symptoms (nausea, diarrhea, vomiting), fatigue, musculoskeletal pain, and liver enzyme elevations. Krazati may cause serious adverse effects including hepatotoxicity and QT prolongation. Patients should be monitored regularly during treatment. Drug interactions may occur with certain medications, so patients should inform their healthcare provider of all medications and supplements they are taking. This medication should be taken exactly as prescribed by the treating oncologist.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy